1
|
Yang JS, Gao FF, Yang XX, Liang F, Yang ZJ, Chen J, Zhang YX, Yan CX. The 5-HT 7 receptors in the VLO contribute to the development of morphine-induced behavioral sensitization in rats. Neurochem Int 2023:105566. [PMID: 37339717 DOI: 10.1016/j.neuint.2023.105566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 05/09/2023] [Accepted: 06/13/2023] [Indexed: 06/22/2023]
Abstract
The 5-hydroxytryptamine 7 receptor (5-HT7R) is one of the most recently cloned serotonin receptors which have been implicated in many physiological and pathological processes including drug addiction. Behavioral sensitization is the progressive process during which re-exposure to drugs intensified the behavioral and neurochemical responses to drugs. Our previous study has demonstrated that the ventrolateral orbital cortex (VLO) is critical for morphine-induced reinforcing effect. The aim of the present study was to investigate the effect of 5-HT7Rs in the VLO on morphine-induced behavioral sensitization and their underlying molecular mechanisms. Our results showed that a single injection of morphine, followed by a low challenge dose could induce behavioral sensitization. Microinjection of the selective 5-HT7R agonist AS-19 into the VLO during the development phase significantly increased morphine-induced hyperactivity. Microinjection of the 5-HT7R antagonist SB-269970 suppressed acute morphine-induced hyperactivity and the induction of behavioral sensitization, but had no effect on the expression of behavioral sensitization. In addition, the phosphorylation of AKT (Ser 473) was increased during the expression phase of morphine-induced behavioral sensitization. Suppression of the induction phase could also block the increase of p-AKT (Ser 473). In conclusion, we demonstrated that 5-HT7Rs and p-AKT in the VLO at least partially contribute to morphine-induced behavioral sensitization.
Collapse
Affiliation(s)
- Jing-Si Yang
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China
| | - Fei-Fei Gao
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China
| | - Xi-Xi Yang
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China
| | - Feng Liang
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China
| | - Zhuo-Jin Yang
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China
| | - Jie Chen
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China
| | - Yu-Xiang Zhang
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China.
| | - Chun-Xia Yan
- College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; The Key Laboratory of Forensic Medicine (Xi'an Jiaotong University) of the National Health Commission, Xi'an, Shaanxi, 710061, China; Academy of Bio-evidence Science, Science and Technology Innovation Port in Western China, Xi'an Jiaotong University, Xi-Xian New District, Shaanxi, 710115, China.
| |
Collapse
|
2
|
de Natale ER, Wilson H, Politis M. Serotonergic imaging in Parkinson's disease. PROGRESS IN BRAIN RESEARCH 2021; 261:303-338. [PMID: 33785134 DOI: 10.1016/bs.pbr.2020.11.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive degeneration of monoaminergic central pathways such as the serotonergic. The degeneration of serotonergic signaling in striatal and extrastriatal brain regions is an early feature of PD and is associated with several motor and non-motor complications of the disease. Molecular imaging techniques with Positron Emission Tomography (PET) have greatly contributed to the investigation of biological changes in vivo and to the understanding of the extent of serotonergic pathology in patients or individuals at risk for PD. Such discoveries provide with opportunities for the identification of new targets that can be used for the development of novel disease-modifying drugs or symptomatic treatments. Future studies of imaging serotonergic molecular targets will better clarify the importance of serotonergic pathology in PD, including progression of pathology, target-identification for pharmacotherapy, and relevance to endogenous synaptic serotonin levels. In this article, we review the current status and understanding of serotonergic imaging in PD.
Collapse
Affiliation(s)
| | - Heather Wilson
- Neurodegeneration Imaging Group, University of Exeter Medical School, London, United Kingdom
| | - Marios Politis
- Neurodegeneration Imaging Group, University of Exeter Medical School, London, United Kingdom.
| |
Collapse
|
3
|
Blattner KM, Canney DJ, Pippin DA, Blass BE. Pharmacology and Therapeutic Potential of the 5-HT 7 Receptor. ACS Chem Neurosci 2019; 10:89-119. [PMID: 30020772 DOI: 10.1021/acschemneuro.8b00283] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
It is well-documented that serotonin (5-HT) exerts its pharmacological effects through a series of 5-HT receptors. The most recently identified member of this family, 5-HT7, was first identified in 1993. Over the course of the last 25 years, this receptor has been the subject of intense investigation, and it has been demonstrated that 5-HT7 plays an important role in a wide range of pharmacological processes. As a result of these findings, modulation of 5-HT7 activity has been the focus of numerous drug discovery and development programs. This review provides an overview of the roles of 5-HT7 in normal physiology and the therapeutic potential of this interesting drug target.
Collapse
Affiliation(s)
- Kevin M. Blattner
- Temple University School of Pharmacy, Department of Pharmaceutical Sciences, Moulder Center for Drug Discovery Research, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States
| | - Daniel J. Canney
- Temple University School of Pharmacy, Department of Pharmaceutical Sciences, Moulder Center for Drug Discovery Research, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States
| | - Douglas A. Pippin
- Praeventix, LLC, 665 Stockton Drive, Suite 200H, Exton, Pennsylvania 19341, United States
| | - Benjamin E. Blass
- Temple University School of Pharmacy, Department of Pharmaceutical Sciences, Moulder Center for Drug Discovery Research, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States
| |
Collapse
|
4
|
Hauser SR, Hedlund PB, Roberts AJ, Sari Y, Bell RL, Engleman EA. The 5-HT7 receptor as a potential target for treating drug and alcohol abuse. Front Neurosci 2015; 8:448. [PMID: 25628528 PMCID: PMC4292232 DOI: 10.3389/fnins.2014.00448] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Accepted: 12/19/2014] [Indexed: 12/18/2022] Open
Abstract
Alcohol and drug abuse take a large toll on society and affected individuals. However, very few effective treatments are currently available to treat alcohol and drug addiction. Basic and clinical research has begun to provide some insights into the underlying neurobiological systems involved in the addiction process. Several neurotransmitter pathways have been implicated and distinct reward neurocircuitry have been proposed—including the mesocorticolimbic dopamine (MCL-DA) system and the extended amygdala. The serotonin (5-HT) neurotransmitter system is of particular interest and multiple 5-HT receptors are thought to play significant roles in alcohol and drug self-administration and the development of drug dependence. Among the 5-HT receptors, the 5-HT7 receptor is currently undergoing characterization as a potential target for the treatment of several psychiatric disorders. Although this receptor has received only limited research regarding addictive behaviors, aspects of its neuroanatomical, biochemical, physiological, pharmacological, and behavioral profiles suggest that it could play a key role in the addiction process. For instance, genomic studies in humans have suggested a link between variants in the gene encoding the 5-HT7 receptor and alcoholism. Recent behavioral testing using high-affinity antagonists in mice and preliminary tests with alcohol-preferring rats suggest that this receptor could mediate alcohol consumption and/or reinforcement and play a role in seeking/craving behavior. Interest in the development of new and more selective pharmacological agents for this receptor will aid in examining the 5-HT7 receptor as a novel target for treating addiction.
Collapse
Affiliation(s)
- Sheketha R Hauser
- Department of Psychiatry, Indiana University School of Medicine Indianapolis, IN, USA
| | - Peter B Hedlund
- Department of Molecular and Cellular Neuroscience, The Scripps Research Institute La Jolla, CA, USA
| | - Amanda J Roberts
- Department of Molecular and Cellular Neuroscience, The Scripps Research Institute La Jolla, CA, USA ; Molecular and Cellular Neuroscience Department, Mouse Behavioral Assessment Core, The Scripps Research Institute La Jolla, CA, USA
| | - Youssef Sari
- Department of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Toledo, OH, USA
| | - Richard L Bell
- Department of Psychiatry, Indiana University School of Medicine Indianapolis, IN, USA
| | - Eric A Engleman
- Department of Psychiatry, Indiana University School of Medicine Indianapolis, IN, USA
| |
Collapse
|
6
|
Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. DRUG DESIGN DEVELOPMENT AND THERAPY 2012; 6:107-15. [PMID: 22675261 PMCID: PMC3367402 DOI: 10.2147/dddt.s11180] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Lurasidone is a novel benzisothiazole antipsychotic drug for the treatment of schizophrenia. Of the antipsychotic drugs, lurasidone has the highest affinity for the 5-hydroxytryptamine (5-HT)7 receptor. Lurasidone also has high affinities for the dopamine D2, 5HT2A, 5-HT1A and α2C adrenergic receptors. Moreover, lurasidone has low affinities for the α1 adrenergic, histamine H1 and muscarinic M1 receptors. The involvement of 5-HT7 receptors in cognitive processes has been suggested by both pharmacological and molecular investigations. Chronic treatment with lurasidone increases neurotrophin BDNF mRNA levels in both the hippocampus (ventral and dorsal) and prefrontal cortex under basal conditions or in response to an acute swim stress. Lurasidone may potentiate N-methyl-D-aspartate receptor (NMDAR) function through antagonistic action on 5-HT7 receptors without a direct affinity for NMDARs. These results suggest that lurasidone treatment may be a novel approach for the prevention of the development of cognitive impairment in individuals who are at risk for schizophrenia or related disorders involving cognitive impairment. In clinical trials, treatment with lurasidone was associated with significantly greater endpoint improvement versus placebo on the Positive and Negative Syndrome Scale total score after 6 weeks among subjects receiving 80 or 160 mg. The most frequent side effects of lurasidone were akathisia, nausea, parkinsonism, dizziness and somnolence. Once-daily treatment with lurasidone at 160 mg was superior to placebo based on the composite cognitive functioning measure. Lurasidone treatment produced improvements in Montgomery–Asberg Depression Rating Scale scores at 6 weeks that were significantly greater than placebo. A limitation of this review is that the majority of the data were obtained from abstracts and posters. These sources have not been subjected to the peer review processes of medical journals; thus, the results presented in these forums may require further quality review and subsequent revision prior to final publication.
Collapse
Affiliation(s)
- Norio Yasui-Furukori
- Department of Neuropsychiatry, Hirosaki University School of Medicine, Aomori, Japan.
| |
Collapse
|